share_log

白云山(600332.SH):BYS30颗粒获得药物临床试验批准通知书

BAIYUNSHAN PH (600332.SH): The BYS30 particles have received the drug clinical trial approval notification.

Gelonghui Finance ·  Jan 9 19:02

On January 9, Gelonghui reported that BAIYUNSHAN PH (600332.SH) announced that its subsidiary, Guangzhou BAIYUNSHAN Pharmaceutical Group Co., Ltd., received the "Clinical Trial Approval Notification" issued by the National Medical Products Administration for the drug named: BYS30 Granules. BYS30 Granules is a Class 1 innovative Traditional Chinese Medicine compound formulation developed by the BAIYUNSHAN Pharmaceutical Factory, indicated for knee osteoarthritis.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment